Preferred Label : Rifaximin;

MeSH definition : A synthetic rifamycin derivative and anti-bacterial agent that is used for the treatment of GASTROENTERITIS caused by ESCHERICHIA COLI INFECTIONS. It may also be used in the treatment of HEPATIC ENCEPHALOPATHY.;

MeSH synonym : 4-Deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4C)rifamycin;

MeSH hyponym : L-105; L105;

MeSH CAS label : 2,7-(Epoxy(1,11,13)pentadecatrienoimino)furo(2'',3'':7',8')naphth(1',2':4,5)imidazo(1,2-a)pyridine-1,15(2H)-dione, 25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-, ( 2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-;

Wikipedia link : https://en.wikipedia.org/wiki/Rifaximin;

UNII : L36O5T016N;

Details


Main resources

You can consult :

A synthetic rifamycin derivative and anti-bacterial agent that is used for the treatment of GASTROENTERITIS caused by ESCHERICHIA COLI INFECTIONS. It may also be used in the treatment of HEPATIC ENCEPHALOPATHY.

https://www.cochrane.org/fr/CD011585/LIVER_la-rifaximine-pour-la-prevention-et-le-traitement-de-lencephalopathie-hepatique-chez-les-personnes
2023
United Kingdom
review of literature
french abstract
preventive treatment, nos
disease of liver, nos
disease
hepatic encephalopathy
persons
cirrhosis of liver, nos
Encephalopathy
Rifaximin
Cirrhosis
hepatic encephalopathy
liver cirrhosis

---
https://www.has-sante.fr/jcms/p_3280963/fr/targaxan-rifaximine
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, oral
gastrointestinal agents
rifaximin
anti-bacterial agents
recurrence
hepatic encephalopathy
Product containing precisely rifaximin 550 milligram/1 each conventional release oral tablet (clinical drug)
evaluation of the transparency committee
Rifaximin

---
https://www.has-sante.fr/jcms/p_3280941/fr/tixtar-rifaximine
2021
false
false
false
France
gastrointestinal agents
anti-bacterial agents
rifaximin
Hepatic encephalopathy prophylaxis
recurrence
hepatic encephalopathy
administration, oral
insurance, health, reimbursement
treatment outcome
evaluation of the transparency committee
Rifaximin

---
http://www.has-sante.fr/portail/jcms/c_2579407/fr/tixtar
http://www.has-sante.fr/portail/jcms/c_2579407/fr/tixtar-rifaximine-anti-infectieux-intestinal
2015
false
false
false
false
France
French
evaluation of the transparency committee
rifaximin
administration, oral
treatment outcome
insurance, health, reimbursement
recurrence
hepatic encephalopathy
gastrointestinal agents
gastrointestinal agents
nucleic acid synthesis inhibitors
nucleic acid synthesis inhibitors
anti-infective agents
anti-infective agents
adult
guidelines for drug use
Hepatic encephalopathy prophylaxis
rifamycins
rifamycins
Rifaximin
Rifaximin

---
http://www.has-sante.fr/portail/jcms/c_2579431/fr/targaxan
2015
false
false
false
false
France
French
evaluation of the transparency committee
rifaximin
administration, oral
treatment outcome
insurance, health, reimbursement
recurrence
hepatic encephalopathy
gastrointestinal agents
gastrointestinal agents
nucleic acid synthesis inhibitors
nucleic acid synthesis inhibitors
anti-infective agents
anti-infective agents
adult
rifamycins
rifamycins
Rifaximin
Rifaximin

---
Nous contacter.
05/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.